To establish clinical relevance, we investigated further using larger cohorts SCAN-B and METABRIC of breast cancer patients data analysis suggested that LCN2 expression score is high in aggressive breast cancer HER2+ or TNBC, but not linked with any survival outcome of these subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.